Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard vs Histotype-Tailored Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcoma
NCT01710176Phase 3Completed
- Sponsor
- Italian Sarcoma Group
- Start
- Jun 2011
- Primary completion
- Jun 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of trabectedin, gemcitabine, dacarbazine, docetaxel, etoposide in soft tissue sarcoma (STS), sponsored by Italian Sarcoma Group. Started Jun 2011; status: completed.
02
Drugs
trabectedingemcitabinedacarbazinedocetaxeletoposide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT01710176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01710176.